Thomas Wessel

Thomas C. Wessel is an accomplished drug developer with over 25 years of experience in the biopharmaceutical industry, specializing in CNS drug development from preclinical stages through phase 4. He has served as a medical lead for three approved NDAs, demonstrating his expertise and leadership in the field.

His educational background includes a PhD in Neurobiology from the Max Planck Institute for Psychiatry in Martinsried, an MD from Ludwig Maximilians University in Munich, and a Neurology residency at Cornell University Medical College, where he also obtained board certification.

Thomas has held various significant roles in renowned organizations, including being the Executive Vice President of R&D at Relmada Therapeutics, Inc., Chief Medical Officer at Asceneuron SA, Flex Pharma, and Acorda Therapeutics, President at Berkshire Drug Development Consulting, LLC, SVP of Clinical Research at Sepracor, and Executive Director at Janssen-Cilag. He has also contributed as an Assistant Professor at Cornell University Medical College.

His expertise spans across translational medicine, clinical development, pharmacovigilance, regulatory affairs, and new product strategy, showcasing his diverse skill set and extensive knowledge in the pharmaceutical domain. Thomas's background and experience make him a highly sought-after Clinical Development Consultant, leveraging his comprehensive understanding of the industry to drive successful drug development initiatives.